Search

Your search keyword '"Beeker, Aart"' showing total 186 results
Start Over Author "Beeker, Aart"
186 results on '"Beeker, Aart"'

3. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

Author

Badrising, Sushil K., Louhanepessy, Rebecca D., van der Noort, Vincent, Kieffer, Jacobien, Coenen, Jules L. L. M., Hamberg, Paul, Beeker, Aart, Wagenaar, Nils, Lam, Marnix, Celik, Filiz, Loosveld, Olaf J. L., Oostdijk, Ad, Zuetenhorst, Hanneke, de Feijter, Jeantine M., Dezentjé, Vincent O., Ras-van Spijk, Suzan, Vegt, Erik, Haanen, John B., van de Poll-Franse, Lonneke V., Zwart, Wilbert, and Bergman, Andries M.

Published
2022
Full Text
View/download PDF

5. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A. M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert-Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J. W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W. C. J., van der Spek, Ellen, Leys, Rineke B. L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C. H. P., Sinnige, Harm A. M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark-David, and Zweegman, Sonja

Published
2021
Full Text
View/download PDF

6. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.

Author

Bromberg, Jacoline E C, Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C, Seute, Tatjana, Durian, Marc, Cull, Gavin, Poel, Marjolein W M van der, Stevens, Wendy B C, Zijlstra, Josee M, Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D, Beeker, Aart, Abrahamse-Testroote, Martine C J, Bent, Martin J van den, Jong, Daphne de, and Doorduijn, Jeanette K

Published
2024
Full Text
View/download PDF

7. P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.

Author

Kersting, Sabina, primary, Levin, Mark-David, additional, Dubois, Julie, additional, van Norden, Yvette, additional, Dobber, Johan, additional, Jauw, Yvonne, additional, van der Kevie-Kersemaekers, Anne-Marie, additional, Mellink, Clemens, additional, Da Cunha-Bang, Caspar, additional, Van Desr Burg, Leonie, additional, Te Raa, Doreen, additional, de Boer, Fransien, additional, Droogendijk, Jolanda, additional, Idink, Cecile, additional, De Heer, Koen, additional, Nijziel, Marten, additional, Tick, Lidwine, additional, Ludwig, Inge, additional, Silbermann, Mathijs, additional, Beeker, Aart, additional, Bellido, Mar, additional, Evers, Ludo, additional, Zwezerijnen, Gerben, additional, Zijlstra, Josée, additional, Kap, Marcel, additional, Niemann, Carsten, additional, and Kater, Arnon, additional

Published
2023
Full Text
View/download PDF

9. Supplementary Table 4 from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

Author

Nieuweboer, Annemieke J.M., primary, de Graan, Anne-Joy M., primary, Hamberg, Paul, primary, Bins, Sander, primary, van Soest, Robert J., primary, van Alphen, Robbert J., primary, Bergman, Andries M., primary, Beeker, Aart, primary, van Halteren, Henk, primary, ten Tije, Albert J., primary, Zuetenhorst, Hanneke, primary, van der Meer, Nelly, primary, Chitu, Dana, primary, de Wit, Ronald, primary, and Mathijssen, Ron H.J., primary

Published
2023
Full Text
View/download PDF

10. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Author

Nijhof, Inger S., Franssen, Laurens E., Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Ypma, Paula F., Raymakers, Reinier, van Spronsen, Dick-Johan, Westerweel, Peter E., Oostvogels, Rimke, van Velzen, Jeroen, van Kessel, Berris, Mutis, Tuna, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., and van de Donk, Niels W.C.J.

Published
2016
Full Text
View/download PDF

11. Mucositis-Associated Bloodstream Infections in Haematology Patients with Fever During Neutropenia

Author

de Jonge, Nick Alexander, primary, Janssen, Jeroen J.W.M., additional, Ypma, Paula, additional, Herbers, Alexandra H., additional, de Kreuk, Arne, additional, Vasmel, Wies, additional, van den Ouweland, Jody M.W., additional, Beeker, Aart, additional, Visser, Otto, additional, Zweegman, Sonja, additional, Blijlevens, Nicole M.A., additional, van Agtmael, Michiel A., additional, and Sikkens, Jonne J., additional

Published
2023
Full Text
View/download PDF

16. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

17. Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Author

Levin, Mark-David, primary, Kersting, Sabina, additional, Dubois, Julie M.N., additional, Norden, Yvette, additional, Dobber, Johan A, additional, Jauw, Yvonne W.S., additional, Kevie-Kersemaekers, Anne-Marie van der, additional, Mellink, Clemens, additional, Heer, Koen de, additional, Burg, Leonie van der, additional, Raa, Doreen Te, additional, Boer, Fransien de, additional, Droogendijk, Jolanda, additional, Idink, Cecile, additional, Nijziel, Marten R., additional, Tick, Lidwine W., additional, Ludwig, Inge, additional, Silbermann, Matthijs, additional, Beeker, Aart, additional, Bellido, Mar, additional, Evers, Ludo M., additional, Zwezerijnen, Gerben JC, additional, Niemann, Carsten U, additional, and Kater, Arnon P., additional

Published
2022
Full Text
View/download PDF

18. Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Author

van der Pol, Ymke, primary, Wang, Steven, additional, Moldovan, Norbert, additional, de Jonge, A.Vera, additional, Drees, Esther E.E., additional, Roemer, Margaretha, additional, Ylstra, Bauke, additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, de Heer, Koen, additional, Klerk, Clara, additional, van Rijn, Rozemarijn, additional, Fijnheer, Rob, additional, Vergote, Vibeke K.J., additional, Beeker, Aart, additional, Nieuwenhuizen, Laurens, additional, Mous, Rogier, additional, Vermaat, Joost S.P., additional, Pegtel, D. Michiel, additional, Chamuleau, Martine E.D., additional, and Mouliere, Florent, additional

Published
2022
Full Text
View/download PDF

19. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial

Author

van Dodewaard-de Jong, Joyce M., de Klerk, John M. H., Bloemendal, Haiko J., Oprea-Lager, Daniela E., Hoekstra, Otto S., van den Berg, H. Pieter, Los, Maartje, Beeker, Aart, Jonker, Marianne A., O’Sullivan, Joe M., Verheul, Henk M. W., and van den Eertwegh, Alfons J. M.

Published
2017
Full Text
View/download PDF

20. First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Author

Goldberg, Stuart L., Cortes, Jorge E., Gambacorti‐Passerini, Carlo, Hehlmann, Rüdiger, Khoury, H. Jean, Michallet, Mauricette, Paquette, Ron L., Simonsson, Bengt, Zyczynski, Teresa, Foreman, Aimee, Abruzzese, Elisabetta, Andorsky, David, Beeker, Aart, Cony‐Makhoul, Pascale, Hansen, Richard, Lomaia, Elza, Olavarria, Eduardo, and Mauro, Michael J.

Published
2017
Full Text
View/download PDF

21. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study

Author

Meulendijks, Didier, Beerepoot, Laurens V., Boot, Henk, de Groot, Jan Willem B., Los, Maartje, Boers, James E., Vanhoutvin, Steven A. L. W., Polee, Marco B., Beeker, Aart, Portielje, Johanna E. A., de Jong, Robert S., Goey, Swan H., Kuiper, Maria, Sikorska, Karolina, Beijnen, Jos H., Tesselaar, Margot E., Schellens, Jan H. M., and Cats, Annemieke

Published
2016
Full Text
View/download PDF

22. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Author

Meulendijks, Didier, de Groot, Jan Willem B., Los, Maartje, Boers, James E., Beerepoot, Laurens V., Polee, Marco B., Beeker, Aart, Portielje, Johanna E.A., Goey, Swan H., de Jong, Robert S., Vanhoutvin, Steven A.L.W., Kuiper, Maria, Sikorska, Karolina, Pluim, Dick, Beijnen, Jos H., Schellens, Jan H.M., Grootscholten, Cecile, Tesselaar, Margot E.T., and Cats, Annemieke

Published
2016
Full Text
View/download PDF

23. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

Author

Badrising, Sushil K., primary, Louhanepessy, Rebecca D., additional, van der Noort, Vincent, additional, Kieffer, Jacobien, additional, Coenen, Jules L. L. M., additional, Hamberg, Paul, additional, Beeker, Aart, additional, Wagenaar, Nils, additional, Lam, Marnix, additional, Celik, Filiz, additional, Loosveld, Olaf J. L., additional, Oostdijk, Ad, additional, Zuetenhorst, Hanneke, additional, de Feijter, Jeantine M., additional, Dezentjé, Vincent O., additional, Ras-van Spijk, Suzan, additional, Vegt, Erik, additional, Haanen, John B., additional, van de Poll-Franse, Lonneke V., additional, Zwart, Wilbert, additional, and Bergman, Andries M., additional

Published
2021
Full Text
View/download PDF

25. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide:II HOVON trial results of a multicenter

Author

Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, and Kersten, Marie José

Abstract

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).

Published
2020

26. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide: II HOVON trial results of a multicenter

Author

Chamuleau, Martine E. D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S. P., Marijt, Eric A. F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J. F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I. J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, Kersten, Marie José, Hematology, CCA - Cancer Treatment and quality of life, Internal medicine, Oral and Maxillofacial Surgery / Oral Pathology, Pathology, Radiology and nuclear medicine, CCA - Imaging and biomarkers, AGEM - Re-generation and cancer of the digestive system, AII - Cancer immunology, Erasmus MC other, Radiotherapy, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life

Abstract

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).

Published
2020

27. First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).

Author

van der Zande, Kim, primary, van der Noort, Vincent, additional, Busard, Milou, additional, Hamberg, Paul, additional, Ras - van Spijk, Suzan, additional, De Feijter, Jeantine, additional, Dezentjé, Vincent O., additional, Tascilar, Metin, additional, Houtsma, Danny, additional, Beeker, Aart, additional, van den Berg, H Pieter, additional, ten Oever, Diederik, additional, Oving, Irma M., additional, Zwart, Wilbert, additional, and Bergman, Andre M., additional

Published
2021
Full Text
View/download PDF

28. Short Versus Extended Treatment with a Carbapenem in Haematology Patients with High Risk Fever of Unknown Origin During Neutropenia: An Open-Label Multicentre Randomised Clinical Trial

Author

de Jonge, Nick Alexander, primary, Sikkens, Jonne J., additional, Zweegman, Sonja, additional, Beeker, Aart, additional, Ypma, Paula, additional, Herbers, Alexandra H., additional, Vasmel, Wies, additional, de Kreuk, Arne, additional, Coenen, Juleon L.L.M., additional, Lissenberg-Witte, Birgit I., additional, Kramer, Mark H.H., additional, van Agtmael, Michiel A., additional, and Janssen, Jeroen J.W.M., additional

Published
2021
Full Text
View/download PDF

29. Extent of radiological response does not reflect survival in primary central nervous system lymphoma

Author

van der Meulen, Matthijs, primary, Postma, Alida A, additional, Smits, Marion, additional, Bakunina, Katerina, additional, Minnema, Monique C, additional, Seute, Tatjana, additional, Cull, Gavin, additional, Enting, Roelien H, additional, van der Poel, Marjolein, additional, Stevens, Wendy B C, additional, Brandsma, Dieta, additional, Beeker, Aart, additional, Doorduijn, Jeanette K, additional, Issa, Samar, additional, van den Bent, Martin J, additional, and Bromberg, Jacoline E C, additional

Published
2021
Full Text
View/download PDF

30. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): Study protocol for a trial within a cohort study

Author

Schraa, S. J., Van Rooijen, K. L., Van Der Kruijssen, D. E.W., Rubio Alarcón, C., Phallen, J., Sausen, M., Simmons, J., Coupé, V. M.H., Van Grevenstein, W. M.U., Elias, S., Verkooijen, H. M., Laclé, M. M., Bosch, L. J.W., Van Den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J.A., Vink, G. R., Koopman, M., Dunker, Mich S., Lutke Holzik, Martijn F., Hoekstra, Ronald, Sommeijer, Dirkje W., Van Der Bilt, Jarmila D.W., Consten, Esther C.J., Cirkel, Geert A., Burghgraef, Thijs A., Van Der Schans, Emma M., Nieboer, Peter, Rietbroek, Ron C., Dekker, Jan Willem T., Verschoor, Arjan J., Talsma, Koen A.K., Brosens, Rebecca P.M., Helgason, Helgi H., Marinelli, Andreas W.K.S., De Hingh, Ignace H.J.T., Oldenhuis, Corina N., Jansen, Jan, Van Halteren, Henk K., Stockmann, Hein B.A.C., Beeker, Aart, Bosscha, Koop, Pruijt, Hans F.M., Spierings, Leontine E.A.M.M., Valkenburg-Van Iersel, Liselot B.J., Vles, Wouter J., De Jongh, Felix E., Van Cruijsen, Hester, Heikens, Joost T., Zimmerman, David D.E., Van Alphen, Robert J., Schiphorst, Anandi H.W., Van Leeuwen-Snoeks, Lobke L., Vogelaar, Jeroen F.J., Peters, Natascha A.J.B., Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pathology, Internal medicine, Orthopedic Surgery and Sports Medicine, VU University medical center, Surgery, ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Medical Biology, Nephrology, and Oncology

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Neoplasm, Residual, Colorectal cancer, Cost-Benefit Analysis, COLORECTAL-CANCER, Circulating Tumor DNA, Study Protocol, 0302 clinical medicine, RESIDUAL DISEASE, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Prospective Studies, Colectomy, Netherlands, Randomized Controlled Trials as Topic, RISK, education.field_of_study, RANDOMIZED CONTROLLED-TRIAL, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Colon cancer, Oxaliplatin, Chemotherapy, Adjuvant, CELL-FREE DNA, 030220 oncology & carcinogenesis, Colonic Neoplasms, Practice Guidelines as Topic, SURVIVAL, Female, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Population, TwiCs, lcsh:RC254-282, Disease-Free Survival, LEUCOVORIN, Capecitabine, 03 medical and health sciences, Internal medicine, Genetics, medicine, Biomarkers, Tumor, Humans, RECURRENCE, education, Neoplasm Staging, Intention-to-treat analysis, business.industry, Liquid Biopsy, ctDNA, Patient Acceptance of Health Care, medicine.disease, Minimal residual disease, FLUOROURACIL, Adjuvant chemotherapy, 030104 developmental biology, Quality of Life, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients. Methods/design MEDOCC-CrEATE follows the ‘trial within cohorts’ (TwiCs) design. Patients with colorectal cancer (CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current guidelines, who are randomized 1:1 into an experimental and a control arm. In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group will standard follow-up according to guideline. The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat. Discussion The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population. Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding ethical dilemmas of ctDNA status disclosure in the control group. Trial registration Netherlands Trial Register: NL6281/NTR6455. Registered 18 May 2017, https://www.trialregister.nl/trial/6281

Published
2020

31. Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Bohmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chitu, Dana, Brouwer, Rolf E., and van Imhoff, Gustaaf W.

Subjects
relapse, PLUS RITUXIMAB, IBRITUMOMAB TIUXETAN, diffuse large B-cell lymphoma, MULTICENTER, B-CELL LYMPHOMA, PECC, CHEMOTHERAPY, OPEN-LABEL, TRIAL, Y-90-ibritumomab tiuxetan, COMBINATION, consolidation, ELDERLY-PATIENTS, CHOP
Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with Y-90-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade >= 3 adverse events from start of Y-90-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to Y-90-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after Y-90-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of Y-90-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and Y-90-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with Y-90-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019

32. Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., van Imhoff, Gustaaf W., Hematology, CCA - Cancer Treatment and quality of life, Pathology, AGEM - Re-generation and cancer of the digestive system, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, CCA - Cancer Treatment and Quality of Life, and Clinical Haematology

Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with 90Y-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade ≥3 adverse events from start of 90Y-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to 90Y-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after 90Y-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of 90Y-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33–68%) and 62% (95% CI, 42–77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17–39%) and 49% (95% CI, 36–61%), respectively. Toxicities of R-PECC and 90Y-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with 90Y-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019

33. Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Author

Lugtenburg, Pieternella J, Zijlstra, Josee M, Doorduijn, Jeanette K, Böhmer, Lara H, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, van der Burg-de Graauw, Nicole C, Schouten, Harry C, Bilgin, Yavuz M, Kersten, Marie-Jose, Koene, Harry R, Herbers, Alexandra H E, de Jong, Daphne, Hijmering, Nathalie, Lam, King H, Chiţu, Dana, Brouwer, Rolf E, van Imhoff, Gustaaf W, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology, and Pathology

Subjects
relapse, PLUS RITUXIMAB, IBRITUMOMAB TIUXETAN, diffuse large B-cell lymphoma, MULTICENTER, B-CELL LYMPHOMA, PECC, CHEMOTHERAPY, OPEN-LABEL, TRIAL, Y-90-ibritumomab tiuxetan, COMBINATION, consolidation, ELDERLY-PATIENTS, CHOP
Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with Y-90-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade >= 3 adverse events from start of Y-90-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to Y-90-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after Y-90-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of Y-90-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and Y-90-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with Y-90-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019

34. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Author

Lugtenburg, Pieternella Johanna, primary, de Nully Brown, Peter, additional, van der Holt, Bronno, additional, D’Amore, Francesco A., additional, Koene, Harry R., additional, de Jongh, Eva, additional, Fijnheer, Rob, additional, van Esser, Joost W., additional, Böhmer, Lara H., additional, Pruijt, Johannes F., additional, Verhoef, Gregor E., additional, Hoogendoorn, Mels, additional, Bilgin, Memis Y., additional, Nijland, Marcel, additional, van der Burg-de Graauw, Nicole C., additional, Oosterveld, Margreet, additional, Jie, Kon-Siong G., additional, Larsen, Thomas Stauffer, additional, van der Poel, Marjolein W., additional, Leijs, Maria B., additional, Silbermann, Matthijs H., additional, van Marwijk Kooy, Marinus, additional, Beeker, Aart, additional, Kersten, Marie J., additional, Doorduijn, Jeanette K., additional, Tick, Lidwine W., additional, Brouwer, Rolf E., additional, Lam, King H., additional, Burggraaff, Coreline N., additional, de Keizer, Bart, additional, Arens, Anne I., additional, de Jong, Daphne, additional, Hoekstra, Otto S., additional, and Zijlstra-Baalbergen, Josée M., additional

Published
2020
Full Text
View/download PDF

35. 199. Short versus Extended Antibiotic Treatment with a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients with Fever of Unknown Origin: A Randomized Multicenter Noninferiority Trial

Author

de Jonge, Nick A, primary, Sikkens, Jonne, additional, Zweegman, Sonja, additional, Beeker, Aart, additional, Ypma, Paula, additional, Herbers, Alexandra, additional, Vasmel, Wies, additional, de Kreuk, Arne, additional, Coenen, Juleon, additional, Lissenberg-Witte, Birgit, additional, Budding, Andries, additional, Kramer, Mark, additional, Van Agtmael, Michiel, additional, and Janssen, Jeroen, additional

Published
2020
Full Text
View/download PDF

37. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Author

van der Helm, Lieke H., Alhan, Canan, Wijermans, Pierre W., van Marwijk Kooy, Marinus, Schaafsma, Ron, Biemond, Bart J., Beeker, Aart, Hoogendoorn, Mels, van Rees, Bastiaan P., de Weerdt, Okke, Wegman, Jurgen, Libourel, Ward J., Luykx-de Bakker, Sylvia A., Minnema, Monique C., Brouwer, Rolf E., Croon-de Boer, Fransien, Eefting, Matthijs, Jie, Kon-Siong G., van de Loosdrecht, Arjan A., Koedam, Jan, Veeger, Nic J. G. M, Vellenga, Edo, and Huls, Gerwin

Published
2011
Full Text
View/download PDF

38. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

Author

Stevens, Wendy B.C., primary, Bakunina, Katerina, additional, Cuijpers, Marloes, additional, Chamuleau, Martine, additional, Beeker, Aart, additional, Fijnheer, Rob, additional, Hebart, Holger, additional, Visser, Hein P.J., additional, Doorduijn, Jeanette K., additional, Linton, Kim, additional, Dreyling, Martin, additional, de Jong, Daphne, additional, and Kersten, Marie José, additional

Published
2020
Full Text
View/download PDF

39. Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial

Author

van der Vorst, Maurice J.D.L., primary, Neefjes, Elisabeth C.W., additional, Boddaert, Manon S.A., additional, Verdegaal, Bea A.T.T., additional, Beeker, Aart, additional, Teunissen, Saskia C.C., additional, Beekman, Aartjan T.F., additional, Wilschut, Janneke A., additional, Berkhof, Johannes, additional, Zuurmond, Wouter W.A., additional, and Verheul, Henk M.W., additional

Published
2019
Full Text
View/download PDF

40. Treatment strategies for polycythemia vera: Observations in a Dutch “real‐world” cohort study

Author

van de Ree‐Pellikaan, Claire, primary, de Kreuk, Arne, additional, Schaar, Cees G., additional, Beeker, Aart, additional, Dompeling, Ellen C., additional, Gerrits, Cees J. H., additional, Houten, Anja A., additional, Schipperus, Martin R., additional, Strobbe, Leonie, additional, Posthuma, Eduardus F. M., additional, Klauke, Karin, additional, and Westerweel, Peter E., additional

Published
2019
Full Text
View/download PDF

43. Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel

Author

de Kruijff, Ingeborg E., primary, Sieuwerts, Anieta M., additional, Onstenk, Wendy, additional, Kraan, Jaco, additional, Smid, Marcel, additional, Van, Mai N., additional, van der Vlugt-Daane, Michelle, additional, Oomen-de Hoop, Esther, additional, Mathijssen, Ron H.J., additional, Lolkema, Martijn P., additional, de Wit, Ronald, additional, Hamberg, Paul, additional, Meulenbeld, Hielke J., additional, Beeker, Aart, additional, Creemers, Geert-Jan, additional, Martens, John W.M., additional, and Sleijfer, Stefan, additional

Published
2019
Full Text
View/download PDF

44. Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial

Author

Schuurhuizen, Claudia S.E.W., primary, Braamse, Annemarie M.J., additional, Beekman, Aartjan T.F., additional, Cuijpers, Pim, additional, van der Linden, Mecheline H.M., additional, Hoogendoorn, Adriaan W., additional, Berkhof, Hans, additional, Sommeijer, Dirkje W., additional, Lustig, Vera, additional, Vrijaldenhoven, Suzan, additional, Bloemendal, Haiko J., additional, van Groeningen, Cees J., additional, van Zweeden, Annette A., additional, van der Vorst, Maurice J.D.L., additional, Rietbroek, Ron, additional, Tromp-van Driel, Cathrien S., additional, Wymenga, Machteld N.W., additional, van der Linden, Peter W., additional, Beeker, Aart, additional, Polee, Marco B., additional, Batman, Erdogan, additional, Los, Maartje, additional, van Bochove, Aart, additional, Brakenhoff, Jan A.C., additional, Konings, Inge R.H.M., additional, Verheul, Henk M.W., additional, and Dekker, Joost, additional

Published
2019
Full Text
View/download PDF

45. AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

Author

Sieuwerts, Anieta M., primary, Onstenk, Wendy, additional, Kraan, Jaco, additional, Beaufort, Corine M., additional, Van, Mai, additional, De Laere, Bram, additional, Dirix, Luc Y., additional, Hamberg, Paul, additional, Beeker, Aart, additional, Meulenbeld, Hielke J., additional, Creemers, Geert‐Jan, additional, Weerden, Wytske M., additional, Jenster, Guido W., additional, Nieuweboer, Annemieke J. M., additional, Mathijssen, Ron H. J., additional, Wit, Ronald, additional, Martens, John W. M., additional, and Sleijfer, Stefan, additional

Published
2019
Full Text
View/download PDF

46. Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).

Author

Louhanepessy, Rebecca, primary, Badrising, Sushil, additional, van der Noort, Vincent, additional, Coenen, Jules L. L. M., additional, Hamberg, Paul, additional, Beeker, Aart, additional, Wagenaar, Nils, additional, Lam, Marnix G.E.H., additional, Celik, Filiz, additional, Loosveld, Olaf, additional, Oostdijk, Ad, additional, Zuetenhorst, Johanna Maria, additional, Vegt, Erik, additional, Zwart, Wilbert, additional, and Bergman, Andre M., additional

Published
2019
Full Text
View/download PDF

47. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Author

Bromberg, Jacoline E C, primary, Issa, Samar, additional, Bakunina, Katerina, additional, Minnema, Monique C, additional, Seute, Tatjana, additional, Durian, Marc, additional, Cull, Gavin, additional, Schouten, Harry C, additional, Stevens, Wendy B C, additional, Zijlstra, Josee M, additional, Baars, Joke W, additional, Nijland, Marcel, additional, Mason, Kylie D, additional, Beeker, Aart, additional, van den Bent, Martin J, additional, Beijert, Max, additional, Gonzales, Michael, additional, de Jong, Daphne, additional, and Doorduijn, Jeanette K, additional

Published
2019
Full Text
View/download PDF

48. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Author

Retz, Margitta, primary, Bedke, Jens, additional, Bögemann, Martin, additional, Grimm, Marc-Oliver, additional, Zimmermann, Uwe, additional, Müller, Lothar, additional, Leiber, Christian, additional, Teber, Dogu, additional, Wirth, Manfred, additional, Bolenz, Christian, additional, van Alphen, Robbert, additional, De Santis, Maria, additional, Beeker, Aart, additional, Lehmann, Jan, additional, Indorf, Martin, additional, Frank, Melanie, additional, Bokemeyer, Carsten, additional, and Gschwend, Jürgen E., additional

Published
2019
Full Text
View/download PDF

49. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Author

Franssen, Laurens E., primary, Nijhof, Inger S., additional, Bjorklund, Chad C., additional, Chiu, Hsiling, additional, Doorn, Ruud, additional, van Velzen, Jeroen, additional, Emmelot, Maarten, additional, van Kessel, Berris, additional, Levin, Mark-David, additional, Bos, Gerard M.J., additional, Broijl, Annemiek, additional, Klein, Saskia K., additional, Koene, Harry R., additional, Bloem, Andries C., additional, Beeker, Aart, additional, Faber, Laura M., additional, van der Spek, Ellen, additional, Raymakers, Reinier, additional, Sonneveld, Pieter, additional, Zweegman, Sonja, additional, Lokhorst, Henk M., additional, Thakurta, Anjan, additional, Qian, Xiaozhong, additional, Mutis, Tuna, additional, and van de Donk, Niels W.C.J., additional

Published
2018
Full Text
View/download PDF

50. A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population.

Author

Badrising, Sushil K., Louhanepessy, Rebecca D., Noort, Vincent, Coenen, Jules L.L.M., Hamberg, Paul, Beeker, Aart, Wagenaar, Nils, Lam, Marnix G.E.H., Celik, Filiz, Loosveld, Olaf J.L., Oostdijk, Ad, Zuetenhorst, Hanneke, Haanen, John B., Vegt, Erik, Zwart, Wilbert, and Bergman, Andries M.

Subjects
CASTRATION-resistant prostate cancer, TREATMENT effectiveness, BONE metastasis, PROGRESSION-free survival
Abstract

The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium‐223 dichloride (Ra‐223) over placebo. Here we report clinical outcomes of Ra‐223 treatment in a nonstudy population. In this prospective registry, patients from 20 Dutch hospitals were included prior to Ra‐223 treatment. Clinical parameters collected included previous treatments and Adverse Events. Primary outcome was 6 months Symptomatic Skeletal Event (SSE)‐free survival, while secondary outcomes included Progression‐Free Survival (PFS) and Overall Survival (OS). Of the 305 patients included, 300 were evaluable. The mean age was 73.6 years, 90% had ≥6 bone metastases and 74.1% were pretreated with Docetaxel, 19.5% with Cabazitaxel and 80.5% with Abiraterone and/or Enzalutamide. Of all patients, 96.7% were treated with Ra‐223 and received a median of 5 cycles. After a median follow‐up of 13.2 months, 6 months SSE‐free survival rate was 83%, median PFS was 5.1 months and median OS was 15.2 months. Six months SSE‐free survival rate and OS were comparable with those reported in ALSYMPCA. "Previous Cabazitaxel treatment" and "bone‐only metastases" were independent predictors of a shorter and longer PFS, respectively, while above‐median LDH and "bone‐only metastases" were independent predictors of shorter and longer OS, respectively. Toxicity was similar as reported in the ALSYMPCA trial. These results suggest that in a nonstudy population, Ra‐223 treatment is well‐tolerated, equally effective as in the ALSYMPCA population and that patients not previously treated with Cabazitaxel benefit most from Ra‐223. What's new? The ALSYMCA phase III trial reported a survival benefit from Radium‐223 treatment in patients with metastatic castration‐resistant prostate cancer (mCRPC). These patients, however, were not treated previously with newer life‐prolonging drugs, raising questions about whether the ALSYMCA population reflects current populations of mCRPC patients. In this prospective study, men with mCRPC who were pretreated with newer generation drugs prior to receiving Radium‐223 experienced improvements in disease‐free and overall survival that were comparable to those reported in the ALSYMPCA study. Prior treatment with cabazitaxel independently predicted shorter progression‐free survival. The findings suggest that, overall, Radium‐233 is effective in men with mCRPC. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results